Market requirements · FI
Finland
Fimea has warned against injectable peptides sold through social media. Semaglutide is a prescription medicine in Finland and is not distributed as a research compound.
Buyers in this market search for: peptidit tukkumyynti tutkimus B2B toimittaja.
| Tell us the compounds you need for Finland. | Ask about Finland |
The regime
How compounds are classified in Finland
| Governing law and regulator | Fimea (the Finnish Medicines Agency) is the applicable regulator; its warnings were covered by multiple Finnish outlets in 2026 (Stara.fi, Verkkouutiset, Kymen Sanomat) rather than retrieved from a Fimea primary-source page directly in this research. |
|---|---|
| What the regulator stated | Per this media coverage, Fimea warns against injectable peptides sold via social media, describing their effect on the body as unpredictable, and states that research-chemical peptide preparations sold as peptides lack reliable information on content, quality and safety. Named compounds of concern include BPC-157, TB-500 and Melanotan II. |
| Prescription-only compounds (GLP-1) | Coverage explicitly states semaglutide is a prescription medicine in Finland, is not distributed as a research reagent, and that private imports are restricted - one of the clearest direct GLP-1-specific statements found across all eight markets in this research. |
| Research-use-only framing | Finnish coverage directly addresses this framing, noting some online shops describe products as 'for research use only' to imply non-human use, while injectable formulations carry elevated risk if manufacturing contaminants such as endotoxins are present - the same disclaimer-does-not-change-exposure pattern found in every other market covered. |
| HGH/HCG | Not independently confirmed for Finland in this research; no direct Fimea statement on HGH/HCG specifically was located. Given the EU/EEA framework and the explicit semaglutide statement above, prescription-only status is a reasonable inference but is not source-confirmed for Finland. |
| Already supplying Finland? Send the compounds and volumes you buy today and we will quote against them. | Send your list |
Your obligations
What a buyer in Finland needs settled
- Do not distribute semaglutide, tirzepatide, or other GLP-1 peptides as research reagents into Finland - coverage explicitly restricts private imports and confirms prescription-only status.
- Assume BPC-157, TB-500 and Melanotan II is compounds of specific named regulator concern - do not market them under a research-use disclaimer.
- Do not assume a 'for research use only' label changes legal or safety exposure - Finnish coverage explicitly rejects that framing.
- Confirm HGH/HCG status directly before entry, since no Fimea-specific statement was found and current treatment is inference only.
We will ask about this at enquiry. We check the authorisations your activity requires before quoting, and we confirm the position per compound rather than for the market as a whole.
Sources
Check this yourself
Every position above traces to a dated public document. The authority, the document, the date and the link are below.
| Authority and document | Date | Link |
|---|---|---|
| Stara.fi Secondary media coverage of an authorities' warning about peptides bought online | 2 August 2026 | www.stara.fi/2026/08/02/viranomaisilta-varoitus-verkosta-o... |
| Verkkouutiset Secondary media coverage: 'Do not use these peptides - Fimea warns of serious risks,' including the semaglutide prescription-only statement | undated | www.verkkouutiset.fi/a/ala-kayta-naita-peptideja-fimea-var... |
Links go to the issuing body wherever one exists. Positions change. If you are relying on any of this, check the source rather than this page.
Market brief
Take the Finland brief as a PDF
The regime, the buyer obligations and all 2 sources, dated and linked, in one document you can forward.
Nearby
Nordics and nearby markets
Buyers supplying one of these usually supply the others. The requirements are not the same.
| Code | Market | Sources | |
|---|---|---|---|
| DK | Denmark | 5 sources | Laegemiddelstyrelsen maintains standing warnings, including on Melanotan. Rese... |
| SE | Sweden | 5 sources | Lakemedelsverket has a published position on Melanotan II, and a government-co... |
| PT | Portugal | 5 sources | INFARMED governs medicines under the Estatuto do Medicamento and has flagged a... |
| RO | Romania | 3 sources | ANMDMR operates under the EU medicines framework and has publicly identified a... |
Scope
How to use this page
A summary of the published regulatory position in Finland as at 2026-08-20, written for procurement teams deciding how to source. Every source is dated and linked so it can be checked at origin.
It is not legal advice. Full terms of supply, including where responsibility sits, are set out in our terms of supply.
Questions
Supplying into Finland
Do you supply into Finland?
We supply businesses that hold the authorisations their activity requires. Whether a specific compound can be supplied into Finland depends on that compound and on your authorisations, and we confirm it per compound at the enquiry stage.
Who carries the compliance obligation?
The importer of record and the party placing the product on the market, which is the buyer. We supply the batch documentation that supports your file. We cannot hold your authorisations for you.
How current is this page?
It was reviewed on 2026-08-20 and is scheduled for review again on 2026-11-18. Every source is dated and linked, so you can check the original.
We already supply into Finland. What changes if we source from you?
The batch documentation. You receive a Certificate of Analysis per batch, which can be issued under your own brand. The import and market-placing responsibilities stay where they are.
Is this legal advice?
No. It is a summary of the regulatory positions those authorities have published, as at the review date above. Take advice in your own market before you rely on it.
Enquire about supply into Finland
Tell us the compounds and your authorisations. We confirm per compound before anything ships.